May 19, 2009 08:00 ETAVI BioPharma, Inc. to Present at TIDES 2009 Conference

AVI-4658 Therapeutic for Duchenne Muscular Dystrophy Featured in 'Innovation Showcase'



PORTLAND, OR--(Marketwire - May 19, 2009) - AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that Peter Sazani, Ph.D., Executive Director of Preclinical Development, is presenting an overview of AVI-4658 today at the at the TIDES Oligonucleotide and Peptide Technology and Product… Continue